Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.49
- Piotroski Score 5.00
- Grade Buy
- Symbol (GMAB)
- Company Genmab A/S
- Price $24.33
- Changes Percentage (0.87%)
- Change $0.21
- Day Low $24.23
- Day High $24.43
- Year High $35.88
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $46.00
- High Stock Price Target $53.00
- Low Stock Price Target $31.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.21
- Trailing P/E Ratio 22.95
- Forward P/E Ratio 22.95
- P/E Growth 22.95
- Net Income $4.35 B
Income Statement
Quarterly
Annual
Latest News of GMAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Genmab A/S (GMAB) Stock Price, News, Quote & History - Yahoo Finance
Genmab A/S released new data on the Phase 1/2 study of rinatabart sesutecan (Rina-S), showing a 50% ORR in ovarian cancer patients treated with Rina-S....
By Yahoo! Finance | 6 days ago -
Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers
Genmab A/S (NASDAQ: GMAB) is a biotech company focused on cancer treatments. It ranks 4th on the list of affordable stocks under $40 according to short sellers....
By Yahoo! Finance | 4 weeks ago
